Proclinical trial transparency is up for grabs the FDA and congress are expanding public access to data

摘要

Pressure from patient advocacy groups, Congress, and the National Institutes of Health (NIH) probably had more than a little to do with Johnson & Johnson's announcement in May that it was establishing an outside advisory board to recommend ways J&J can expand access to experimental therapies in its clinical trials. J&J's effort will focus on patients arguing for "compassionate use." Its Janssen Pharmaceutical Companies will pilot the program, but the first experimental drug to be subject to the panel's recommendations has not been named.